{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:10:05Z","timestamp":1782994205446,"version":"3.54.5"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplantation Direct"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>White recipients of 2-haplotype HLA-matched living kidney transplants are perceived to be of low immunologic risk. Little is known about the safety of induction avoidance and calcineurin inhibitor withdrawal in these patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We reviewed our experience at a single center and compared it to Organ Procurement and Transplantation Network (OPTN) registry data and only included 2-haplotype HLA-matched white living kidney transplants recipients between 2000 and 2013.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>There were 56 recipients in a single center (where no induction was given) and 2976 recipients in the OPTN. Among the OPTN recipients, 1285 received no induction, 903 basiliximab, 608 thymoglobulin, and 180 alemtuzumab. First-year acute rejection rates were similar after induction-free transplantation among the center and induced groups nationally. Compared with induction-free transplantation in the national data, there was no decrease in graft failure risk over 13 years with use of basiliximab (adjusted hazard ratio [aHR], 0.86; confidence interval [CI], 0.68-1.08), Thymoglobulin (aHR, 0.92; CI, 0.7-1.21) or alemtuzumab (aHR, 1.18; CI, 0.72-1.93). Among induction-free recipients at the center, calcineurin inhibitor withdrawal at 1 year (n = 27) did not significantly impact graft failure risk (HR,1.62; CI, 0.38-6.89).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study may serve as a foundation for further studies to provide personalized, tailored, immunosuppression for this very low-risk population of kidney transplant patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/txd.0000000000000645","type":"journal-article","created":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T12:02:53Z","timestamp":1486728173000},"page":"e133","source":"Crossref","is-referenced-by-count":5,"title":["The Privilege of Induction Avoidance and Calcineurin Inhibitors Withdrawal in 2 Haplotype HLA Matched White Kidney Transplantation"],"prefix":"10.1097","volume":"3","author":[{"given":"Zaid","family":"Brifkani","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Brennan","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista L.","family":"Lentine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Horwedel","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew F.","family":"Malone","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowena","family":"Delos Santos","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thin Thin","family":"Maw","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Alhamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,3]]},"reference":[{"key":"bib1-20231002","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1600-6143.2009.03009.x","article-title":"Access and outcomes among minority transplant patients, 1999\u20132008, with a focus on determinants of kidney graft survival","volume":"10","year":"2010","journal-title":"Am J Transplant"},{"key":"bib2-20231002","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1001\/jamainternmed.2013.8495","article-title":"Age-related kidney transplant outcomes: health disparities amplified in adolescence","volume":"173","year":"2013","journal-title":"JAMA Intern Med"},{"key":"bib3-20231002","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/TP.0000000000000469","article-title":"Peak panel reactive antibody, cancer, graft, and patient outcomes in kidney transplant recipients","volume":"99","year":"2015","journal-title":"Transplantation"},{"key":"bib4-20231002","doi-asserted-by":"crossref","first-page":"5","DOI":"10.12659\/AOT.881988","article-title":"Outcomes of renal transplantation in recipients with peak panel reactive antibody >30% under tacrolimus-based immunosuppression","volume":"16","year":"2011","journal-title":"Ann Transplant"},{"key":"bib5-20231002","first-page":"662","article-title":"Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells","volume":"2","year":"1966","journal-title":"Lancet"},{"key":"bib6-20231002","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/MOT.0b013e32832d835e","article-title":"The role of major histocompatibility complex class I chain-related gene A antibodies in organ transplantation","volume":"14","year":"2009","journal-title":"Curr Opin Organ Transplant"},{"key":"bib7-20231002","first-page":"261","article-title":"The HLA-matching effect in different cohorts of kidney transplant recipients: 10 years later","year":"2010","journal-title":"Clin Transpl"},{"key":"bib8-20231002","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00007890-198802000-00033","article-title":"Dominant effect of histocompatibility on ten-year kidney transplant survival","volume":"45","year":"1988","journal-title":"Transplantation"},{"key":"bib9-20231002","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJM199209173271202","article-title":"Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors. The UNOS Scientific Renal Transplant Registry","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"key":"bib10-20231002","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1097\/00007890-199606150-00006","article-title":"Determinants of graft survival after renal transplantation","volume":"61","year":"1996","journal-title":"Transplantation"},{"key":"bib11-20231002","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.humimm.2004.06.008","article-title":"HLA matching for kidney transplantation","volume":"65","year":"2004","journal-title":"Hum Immunol"},{"key":"bib12-20231002","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1056\/NEJM199104113241505","article-title":"National allocation of cadaveric kidneys by HLA matching. Projected effect on outcome and costs","volume":"324","year":"1991","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"bib13-20231002","first-page":"1","article-title":"OPTN\/SRTR 2013 Annual Data Report: kidney","volume":"15","year":"2015","journal-title":"Am J Transplant"},{"key":"bib14-20231002","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/ki.1995.452","article-title":"Inferior outcome of two-haplotype matched renal transplants in blacks: Role of early rejection","volume":"48","year":"1995","journal-title":"Kidney Int"},{"key":"bib15-20231002","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00007890-199904150-00013","article-title":"A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients","volume":"67","year":"1999","journal-title":"Transplantation"},{"key":"bib16-20231002","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1681\/ASN.V8111771","article-title":"Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis","volume":"8","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"bib17-20231002","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/TP.0b013e318259407f","article-title":"The implications of acute rejection for allograft survival in contemporary U.S. kidney transplantation","volume":"94","year":"2012","journal-title":"Transplantation"},{"key":"bib18-20231002","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM198409133111103","article-title":"Cyclosporine-associated chronic nephropathy","volume":"311","year":"1984","journal-title":"N Engl J Med"},{"key":"bib19-20231002","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00000478-199301000-00007","article-title":"The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine","volume":"17","year":"1993","journal-title":"Am J Surg Pathol"},{"key":"bib20-20231002","first-page":"1470","article-title":"Interstitial fibrosis in renal allografts in patients treated with cyclosporin","volume":"2","year":"1984","journal-title":"Lancet"},{"key":"bib21-20231002","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1681\/ASN.V12162","article-title":"Cellular and molecular mechanisms of cyclosporin nephrotoxicity","volume":"1","year":"1990","journal-title":"J Am Soc Nephrol"},{"key":"bib22-20231002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2047-1440-3-4","article-title":"Long-term mycophenolate monotherapy in human leukocyte antigen (HLA)-identical living-donor kidney transplantation","volume":"3","year":"2014","journal-title":"Transplant Res"},{"key":"bib23-20231002","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/TP.0b013e318194515c","article-title":"A prospective trial of a steroid-free\/calcineurin inhibitor minimization regimen in human leukocyte antigen (HLA)-identical live donor renal transplantation","volume":"87","year":"2009","journal-title":"Transplantation"},{"key":"bib24-20231002","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/TP.0b013e3182033ef0","article-title":"Calcineurin inhibitor-free monotherapy in human leukocyte antigen\u2013identical live donor renal transplantation","volume":"91","year":"2011","journal-title":"Transplantation"},{"key":"bib25-20231002","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/ndt\/gft447","article-title":"Calcineurin inhibitors in HLA-identical living related donor kidney transplantation","volume":"29","year":"2014","journal-title":"Nephrol Dial Transplant"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01845228-201703000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T07:14:06Z","timestamp":1696230846000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01845228-201703000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000000645","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}